Biotech · Public company · Princeton, NJ, US
PDS Biotechnology Corp
Ticker PDSB · SEC CIK 0001472091
Track this companyFree. Adds PDS Biotechnology Corp to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline3
- Combination Treatment of PDS0101 and PembrolizumabPhase 3 · Recurrent Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab MonotherapyPhase 3 · Recurrent Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®) and PDS0101Phase 2 · Metastatic Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPHASE3 · TERMINATED · started May 30, 2025ClinicalTrials.gov NCT06790966 · fetched Nov 12, 2026
- Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCPHASE2 · COMPLETED · started Mar 29, 2021ClinicalTrials.gov NCT04260126 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026